Newsroom | 86601 results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 1,551,000 shares of its common stock, consisting of stock options to purchase an aggregate of 1,034,000 shares of common stock and restricted stock units (“RSUs”) representing an aggregate of 517,000 shares of common stock, to twelve newly hired employees as an inducement material to their acceptance of em...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards covering an aggregate of 156,650 shares of its common stock to 19 newly hired employees, consisting of inducement stock options to purchase an aggregate of 89,515 shares of common stock and...

DUBLIN--(BUSINESS WIRE)--The "TCR Therapy Market Industry Trends and Global Forecasts to 2035, by Target Indication, Target Antigen, Key Players and Key Geographies" report has been added to ResearchAndMarkets.com's offering. The global TCR therapy market is estimated to grow from USD 0.03 billion in the current year to USD 4.13 billion by 2035, at a CAGR of 51% during the forecast period, till 2035. Cancer continues to be one of the key areas of research and drug development within the pharmac...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company’s common stock to six newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals is providing guidance, expertise...

OXFORD, England--(BUSINESS WIRE)--A new paper, released this week on bioRxiv, introduces hifiasm-ONT, a breakthrough genome assembly algorithm that enables partially phased, near telomere-to-telomere (T2T) assemblies1, using Oxford Nanopore Simplex reads and standard sample prep. Developed by Haoyu Cheng, Han Qu, Heng Li, and Peter Park, with support from Oxford Nanopore’s machine learning and applications teams, this major algorithmic innovation unlocks the length advantage of Oxford Nanopore’...

ABU DHABI, Emirati Arabi Uniti--(BUSINESS WIRE)--Abu Dhabi ha lanciato l'innovativo cluster dedicato al settore delle scienze della vita, rafforzando la sua posizione di hub globale per la biotecnologia, la tecnologia medica e la sanità digitale. Sviluppato dal Dipartimento per lo Sviluppo Economico di Abu Dhabi, dall'Ufficio per gli Investimenti di Abu Dhabi (ADIO) e dal Dipartimento della Salute di Abu Dhabi, il cluster HELM (Health, Endurance, Longevity, and Medicine) è stato progettato per...

ABU DHABI, Verenigde Arabische Emiraten--(BUSINESS WIRE)--Abu Dhabi heeft het baanbrekende life sciences-cluster gelanceerd, waardoor de positie van het land als een wereldwijde hub voor biotechnologie, MedTech en digitale gezondheid wordt versterkt. Het Health, Endurance, Longevity and Medicine (HELM)-cluster is ontwikkeld door het Abu Dhabi Department of Economic Development, Abu Dhabi Investment Office (ADIO) en het Department of Health – Abu Dhabi, en is ontworpen om innovatie in de gezondh...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that the Company’s shareholders are invited to participate in the Combined General Meeting, to be held on Wednesday, May 12, 2025, at 2 pm CET in the premises of the hotel Square Louvois, located at 12, rue de Louvois, 75002, Paris, France....

東京--(BUSINESS WIRE)--(美國商業資訊)-- Rigaku Holdings Corporation旗下子公司Rigaku Corporation（總部：東京昭島市；執行長：Jun Kawakami；以下簡稱「Rigaku」），與SPERA PHARMA, Inc.（總部：大阪市；董事長兼代表董事：Keitaro Iwaki；以下簡稱「SPERA PHARMA」）宣佈達成戰略合作，旨在通過整合雙方尖端技術與深厚專業知識，加速並革新藥物研發進程。 SPERA PHARMA將採用Rigaku提供的電子衍射集成平台XtaLAB Synergy-ED開展合約分析服務，為客戶的藥物研發提供強力支援。 XtaLAB Synergy-ED搭載的3D ED/MicroED1可用於物質結構分析，包括顯微晶體和微量結晶粉末。這項尖端技術具有足夠高的解析度，可以確定原子級結構，從而詳細闡明有機化合物及類似物質的分子結構。 SPERA PHARMA目前是全球醫藥行業唯一一家提供XtaLAB Synergy-ED合約分析服務的企業。Rigaku將為SPERA PHARMA的合約分析業務提供全面...